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DynaminRecent studies provide compelling evidence that HIV-1 entry in cell lines and lymphocytes proceeds by
endocytosis, but these studies are still lacking in macrophages, an important natural target cell for HIV-1.
Macrophages exhibit continual and extensive endocytic activity as part of their natural functions, so we
investigated the uptake pathways involved in productive HIV-1 entry. We ﬁnd that caveolae are not utilised
by HIV-1, because the main structural proteins, caveolin-1 and 2 are absent frommost human leukocytes. We
then focused on macropinocytosis; we ﬁnd that HIV-1 entry into macrophages is sensitive to inhibitors of
Na+/H+ exchange, actin rearrangement, dynamin, Rho family GTPases, and Pak1, but not to inhibitors of PI-3
kinase and myosin II. This leads us to conclude that HIV entry into macrophages proceeds by an endocytic
pathway that is not classical macropinocytosis. Because of the limitations of a purely pharmacological study
such as this, the ﬁnal elucidation of this pathway awaits the development of reliable forward genetic
approaches in authentic macrophages.es).
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Cellular entry of enveloped viruses requires a fusion event
between the cellular membrane and the viral lipid envelope (Marsh
and Helenius, 2006; Smith and Helenius, 2004). Fusion can occur at
the plasma membrane or viruses can be engulfed by the endocytic
machinery and fuse with an endosomal membrane. This endosomal
fusion may be pH-independent or may require exposure to low pH
that triggers conformational changes in the viral fusion protein,
promoting fusion of the viral envelope with the endosomal mem-
brane. Many viruses hijack natural uptake pathways within cells for
rapid and efﬁcient delivery to their nuclear or cytoplasmic sites of
replication. It can be beneﬁcial for viruses to enter via an endosomal
route; for example allowing the bypass of entry barriers such as the
actin cortex or restriction factors, as well as hiding from immune
surveillance systems by leaving no trace on the cell surface. However,
the danger for viruses is that many early endosomal vesicles fuse or
interact with late endosomes, lysosomes or autophagosomes, where
the low pH and degradative enzymes can destroy virus particles.
By using viruses as probes much has been learnt about endocy-
tosis, with these studies highlighting the complicated nature of these
pathways. Initially, all viral endocytic entry was assumed to occur
by clathrin-mediated endocytosis, the most common and earliestcharacterised type of receptor-mediated endocytosis. Viruses are
taken into small clathrin-coated vesicles and transported into early
and late endosomes where low pH and proteases can trigger
uncoating, fusion and release from the endosome. Whilst many
viruses use these pathways, including inﬂuenza, vesicular stomatitis
virus (VSV) and semliki forest virus, entry can also proceed by
clathrin-independent and pH-neutral routes (Marsh and Helenius,
2006). Caveolar pathways are the best characterised of these, through
extensive studies on simian virus 40 (SV40), although their usual role
is in cholesterol homeostasis, cellular transport and signalling. Virus is
taken in by ﬂask-shaped invaginations in the plasma membrane that
have a high concentration of proteins called caveolins, they move to
pH-neutral organelles called caveosomes and then onto the ER where
penetration occurs (Pelkmans et al., 2004; Pelkmans et al., 2005).
Another pathway that has gained much interest recently is
macropinocytosis; this uptake pathway involves non-selective sam-
pling of the extracellular ﬂuid into large vacuoles called macropino-
somes, which are formed from dynamic actin-containing membrane
rufﬂes (Kerr and Teasdale, 2009; Swanson and Watts, 1995). Macro-
pinocytosis is constitutively active in macrophages and immature
dendritic cells (DCs), but is also stimulated by growth factors (such as
platelet derived growth factor, epidermal growth factor and macro-
phage-colony stimulating factor, [M-CSF]), as well as by exposure to
pathogens including Mycobacteria (Garcia-Perez et al., 2008), Salmo-
nella (Alpuche-Aranda et al., 1994) and vaccinia virus (Mercer and
Helenius, 2008; Mercer et al., 2010). It has a strict dependence on
actin rearrangements and some key regulators of actin have been
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kinases (PI-3 kinases), and p21-activated kinase (Pak) (Mercer and
Helenius, 2009). A number of recent studies have described additional
viruses exploiting this route; these include adenovirus 3 and Kaposi
sarcoma herpes virus (Amstutz et al., 2008; Raghu et al., 2009).
As more and more viral entry pathways are being elucidated, the
ﬁeld is becoming somewhat murky with new endocytic routes and
requirements coming to light that do not ﬁt into the three described
pathways (Hansen and Nichols, 2009). Many of these new pathways
differ in their requirement for dynamin, a cytosolic small GTPase that
is responsible for pinching off the internalized endocytic vesicles from
the plasma membrane (Doherty and McMahon, 2009). Phagocytosis
has been shown to be important for the entry of some larger viruses,
for example mimivirus and herpes simplex virus (Clement et al.,
2006; Ghigo et al., 2008). This pathway has many similarities with
macropinocytosis but is induced only in professional phagocytes in
response to pathogens or apoptotic cells.
The early events in HIV-1 entry, in which the viral envelope
protein, gp120–gp41 engages with the primary receptor CD4 on
target cells, are well characterised. This interaction permits confor-
mational changes within gp120 that allow additional binding to a co-
receptor, usually CXCR4 for T-lymphocyte tropic strains, or CCR5 for
macrophage-tropic isolates. Co-receptor binding is the trigger for
virus entry, during which the fusion peptide gp41 inserts into the
cellular membrane to drive the fusion event. However there is some
controversy over the location of this fusion event and it appears to
change depending on the virus strain and cell type. On the whole,
there is a general consensus that cholesterol is required for the fusion
and that receptor molecules are positioned in or proximal to lipid raft
microdomains (Del Real et al., 2002; Kozak et al., 2002; Liao et al.,
2001; Manes et al., 2000; Manes et al., 1999; Nguyen et al., 2005;
Nguyen and Taub, 2002; Percherancier et al., 2003; Popik and Alce,
2004; Popik et al., 2002). Previously, it was generally accepted that
HIV (and other retroviruses) entered by direct fusion at the plasma
membrane. Several lines of evidence led to this opinion. First, HIV
entry is not inhibited by agents preventing vesicle acidiﬁcation and is
pH-independent (McClure et al., 1988; Stein et al., 1987). Second, HIV
Env on the surface of infected cells can induce ‘fusion from without’
with CD4 on target cells at neutral pH (Lifson et al., 1986). Third,
mutant versions of CD4 and CCR5 incapable of inducing endocytosis
could support HIV entry (Bedinger et al., 1988; Brandt et al., 2002;
Maddon et al., 1988; Pelchen-Matthews et al., 1995). Finally, HIV-1
has been shown to have a mechanism for overcoming the post-entry
block of the actin cortex, which would normally act as a barrier to
viruses entering by direct fusion rather than endocytosis. In HeLa cells
it utilises a function of its Nef protein, and in resting T cells, activation
of cellular coﬁlin (Campbell et al., 2004; Yoder et al., 2008).
Many images of HIV in endosomes have been captured, although
these particles were assumed to be on a dead-end degradative route
to late endosomes and lysosomes (Pauza and Price, 1988). However,
there is evidence that the endosomal route of entry can be productive.
First, we know that productive HIV infection can occur when it is
pseudotypedwith the envelope of an unrelated virus (e.g. VSV-G) that
forces it into an endocytic entry route (Aiken, 1997). Second,
inhibitors of vesicle acidiﬁcation can actually promote virus entry by
possibly facilitating virus release from endosomes and preventing
their degradation (Fredericksen et al., 2002; Schaeffer et al., 2004;Wei
et al., 2005). Third, inhibiting the clathrin-mediated endocytosis
machinery using dominant negative inhibitors of dynamin and Eps15
(which interacts with the clathrin adaptor AP2) inhibited HIV entry
into HeLa cells (Daecke et al., 2005). Finally, the most compelling
evidence for endosomal entry of HIV comes from a recent study by
Miyauchi and colleagues. In a time course experiment, they show that
HIV entry becomes resistant to membrane-impermeable fusion
inhibitors if virus is allowed to bind to HeLa cells or CD4+ T cells at
4 °C and enter at 37 °C for a short period, but remains sensitive to atemperature dependent entry block for much longer. Using time-
resolved imaging of single viruses to monitor lipid and content
mixing, they ﬁnd that complete fusion occurs in endosomes and
requires dynamin GTPase, and that although some fusion does occur
at the plasmamembrane, this doesn't result in the completion of virus
entry (Miyauchi et al., 2009).
Much of this work has been performed in cell lines, often with
replication-incompetent virus, mainly due to ease and experimental
reproducibility. However, all of these cells are clinically irrelevant, as
the natural target cells of HIV are predominantly lymphocytes,
macrophages, DCs, and some cells of the central nervous and
reproductive systems. Because of the profound biochemical, structural
and dynamic differences between these primary cells and model cell
lines, there are concerns about the relevance of these ﬁndings to virus
entry in vivo. Some studies have been performed with primary cells
and results point to a confusing picture where entry can be mediated
through many routes. Direct fusion and endocytosis are thought to be
active in CD4+ T lymphocytes (Schaeffer et al., 2004) and direct fusion
is a requisite for productive infection in DCs (Janas et al., 2008). For
macrophages, the macropinocytosis pathway has been implicated
based on observations that HIV was found in very large endosomal
structures shortly after infection and that drugs that speciﬁcally
inhibit macropinocytosis, but not other forms of endocytosis, impair
HIV infection in macrophages. By measuring the presence of cytosolic
p24, researchers claimed that although a number of virions were
subsequently degraded, some penetration of virions into the cytosol
does occur, leading to a productive infection (Marechal et al., 2001).
Macropinocytosis is also thought to be involved in HIV-1 entry into
brain microvascular endothelium; in these cells entry involves lipid
rafts, MAPK signalling, glycosylaminoglycans and ICAM-1 (Liu et al.,
2002). And ﬁnally, entry into placental trophoblasts proceeds by a
clathrin-, caveolae- and dynamin-independent endocytic pathway
requiring membrane cholesterol (Vidricaire and Tremblay, 2007).
Macrophages are of great importance for HIV-1 pathogenesis,
through their contribution to viral persistence, dissemination and
possible transmission (Cassol et al., 2006). For this reason, we are
interested in the productive entry route of viruses into these cells,
especially as macrophages have evolved a variety of strategies for
engulﬁng exogenous material, raising the possibility that alternative
entry and signalling pathways are in operation compared to those
reported for cell lines and lymphocytes.We have previously shown that
HIV entry into macrophages requires membrane cholesterol and lipid
rafts (Carter et al., 2009). Here, we show that cholesterol-dependent
caveolae pathways are not present in macrophages, and therefore
cannot be involved in HIV entry. Using pharmacological inhibitors of
endocytic pathways, we found that productive HIV-1 entry into
macrophages requires a number of factors essential for macropinocy-
tosis, including actin, Rac, and Pak1, while some other macropinocy-
tosis factors are not required.We also ﬁnd a role for dynamin GTPase in
HIV-1 entry and this together with the incomplete requirement for all
important modulators of macropinocytosis leads us to believe that
entry proceeds by a novel pathway that we provisionally name PHEEM,
for “pathway of HIV endocytic entry in macrophages”.
Results
Caveolae are not involved in HIV-1 uptake in macrophages
We have previously shown that virus entry into macrophages
depends on lipid rafts. Using pharmacological inhibitors that disrupt
membrane cholesterol, such as methyl β cyclodextrin, nystatin and
ﬁlipin complex, we showed that productive HIV entry is signiﬁcantly
reduced in the presence of these drugs (Carter et al., 2009). Studies of
this kind are often taken to implicate caveolae as productive uptake
pathways for viruses. All of these drugs have been used to disrupt
caveolae-mediated entry of SV40 (Pelkmans et al., 2002), BK virus
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(Beer et al., 2005). The existence of caveolae and their main structural
protein, caveolin-1 (cav-1), in human leukocytes is controversial
although they have been observed in mouse, rat and bovine
macrophages and human macrophage cell lines (Arakawa et al.,
2000; Baorto et al., 1997; Gargalovic and Dory, 2001; Harris et al.,
2002b; Kiss et al., 2000; Lei and Morrison, 2000). To investigate a
possible role for caveolae in the entry of HIV into macrophages, we
immunoblotted whole cell lysates derived from various human
leukocytes for cav-1. Cav-1 was not detected in human macrophages
that were differentiated in M-CSF (Fig. 1A), granulocyte macrophage-
colony stimulating factor (GM-CSF) (Fig. 1B), or in X-Vivo medium,
nor in macrophages activated by classical and alternative pathways
(Fig. 1C). Also, we did not detect cav-1 in immature or mature DCsFig. 1. Caveolin-1 is not expressed in human macrophages, DCs or CD4+ T lymphocytes. Lys
GM-CSF, or (C) X-Vivo media followed by classical activation with IFNγ and LPS, alternative
anti-cav-1 and GAPDH antibodies. Lysates from (D) immature and LPS matured DCs, (E) fresh
using the same antibodies as above. Data from 2 to 3 donors is shown. The approximate nu
2.5×105 U87.CD4.CCR5 cells were loaded as a positive control in all cases. MΦ=macrophage
and macrophages differentiated in M-CSF (M-MΦ) or GM-CSF (GM-MΦ).(Fig. 1D), monocytes (Fig. 1E) or CD4+ T lymphocytes (Fig. 1F). In
contrast, cav-1 is abundantly expressed as a ~20 kDa protein in our
positive control cells U87.CD4.CCR5. Furthermore, we did not detect
the expression of caveolin-2 in any of the human leukocyte lysates
(data not shown). To conﬁrm the absence of cav-1 expression we
performed RT-PCR analysis with primers to cav-1. Cav-1 expression
was not detected in M-CSF or GM-CSF macrophage cDNA from two
donors (Fig. 1G), whereas positive control primers to ribosomal
protein S15 gene resulted in bands of the expected size. A band of the
correct size for cav-1 was detected in cDNA from U87.CD4.CCR5 cells.
We can conclude that the natural target cells of HIV do not express
caveolins, and cells without these fundamental proteins cannot have
caveolae. Therefore, HIV entry into macrophages is not mediated by
caveolae.ates from macrophages differentiated for 7 days in (A) 100 ng/mL M-CSF, (B) 50 ng/mL
activation with IL-4, or non-activated macrophages were analysed by SDS-PAGE using
ly isolated CD14+monocytes and (F) CD4+ T lymphocytes were analysed by SDS-PAGE
mber of cells loaded (5×105, 1×106 and 2×106) is written above each lane. Lysates of
. (G) Reverse transcription-PCR to detect cav-1 mRNA expression in U87.CD4.CCR5 cells
Fig. 2. Disruption of macropinocytosis with EIPA but not DMA inhibits HIV entry into macrophages. (A) Replication-defective HIV generated by the transfection of 293T cells with
pNL4.3Luc.R-E- and pJRFL envelope was bound onto macrophages at 4 °C for 1 h. Cells were incubated at 37 °C for 15 min in the presence of 70 kDa Dex-TR to allow virus entry.
Macropinosomes were visualised by virtue of Dex-TR ﬂuorescence (red) and virus particles were detected by labelling with anti-p17 antibody (green). The image shows projection
of all Z-stacks taken for 1 cell. Scale bar=10 μm. (B) Cell viability after 1 h treatment with DMA and EIPA was determined using theMTS cytotoxicity assay with the number of viable
cells being expressed as a % of control DMSO treated cells. (C) Productive HIV entry into DMA treated macrophages was measured by detecting late reverse transcription products by
qPCR 28 h p.i., normalised to the number of cells using a β-actin control. (D) HIV-1 replication following DMA treatment was measured by detecting virus in the supernatant
(samples collected regularly from 1 to 15 days p.i.) by p24 ELISA. (E) Productive HIV entry in EIPA treated macrophages was measured by qPCR as before. (F) Inhibition of
macropinocytosis was measured using ﬂow cytometry to detect the uptake of ﬂuid phase ﬂuorescent markers for 30 min at 37 °C in the presence or absence of drugs. Background
binding of the markers to untreated cells at 4 °C was used as a control and subtracted from 37 °C samples. Data represent mean±SD of results obtained with multiple independent
experiments using cells from several donors (3 donors were tested for the MTS assay and p24 data shows 2 donors but is representative of 3). ns — non-signiﬁcant, *signiﬁcant
difference pb0.05, ***extremely signiﬁcant difference pb0.001 (one sample t-test).
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Macropinocytosis has been implicated as a productive entry route
for HIV in macrophages. Virus was observed in large vesicles
resembling macropinosomes and the Na+/H+ exchange inhibitor
DMA decreased p24 release from infected macrophages and reduced
p24 in cytosolic and vesicular compartments early after infection
(Marechal et al., 2001). Macropinosomes are characterised by their
large size (0.2–5 μm) and their inclusion of large ﬂuid phase markers
which are not generally found in smaller clathrin-coated vesicles
(Sallusto et al., 1995). We sought to visualise the early uptake of HIV
in macrophages with 70 kDa Dextran-Texas Red (Dex-TR), the most
commonly used marker of macropinocytosis (Raghu et al., 2009;
Sallusto et al., 1995; Schnatwinkel et al., 2004). If HIV entry proceeds
by this pathway then we would expect to see virus within large
vacuoles co-localising with Dex-TR. HIV NL4.3 pseudotyped with JRFL
envelope was bound to macrophages, warmed to 37 °C in the
presence of Dex-TR to allow entry, then ﬁxed and stained with
antibodies recognising viral p17 protein to visualise the early time
points post-infection (p.i.). At 40 min post entry, z-stack analysis
shows virus co-localising with Dex-TR positive vesicles within the
macrophage (Fig. 2A). However, identical experiments were per-
formed with HIV NL4.3 without virus envelope protein, and this was
also observed to co-localise with Dex-TR positive vesicles. Addition-
ally, both of these viruses were seen to co-localise with markers of
other uptake pathways including transferrin-488 and Cholera Toxin
B-FITC (data not shown). Therefore, a large degree of non-speciﬁc
virus uptake occurs inmacrophages, makingmicroscopy an unreliable
technique for analysing the infection pathway. We therefore relied
upon the use of well-characterised small molecule inhibitors of
speciﬁc cellular pathways together with quantitative PCR of late stage
HIV reverse transcripts to further elucidate the productive infection
pathway.
We sought to determine the effect of macropinocytosis inhibitors
such as amiloride derivatives (West et al., 1989), which block Na+/H+
channels and alter cytosolic pH, on infectious HIV entry. We ﬁrst pre-
treated macrophages for 1 h at 37 °C with DMA at concentrations
proven to be non-toxic by the MTS cytotoxicity assay (Fig. 2B and
Table 1) and then challenged with HIV BaL for 90 min in the absenceTable 1
Cytotoxicity analysis of inhibitors used in this study.a
Inhibitor Mode of action Non-cytot
used in st
BafA Prevents vesicle acidiﬁcation 0.5 μM, 1
Blebbistatin Myosin II inhibitor, prevents membrane blebbing 50 μM, 10
C. difﬁcile Toxin B Rho family GTPase inhibitor 50 ng/mL,
Chlorpromazine Prevents assembly of clathrin-coated pits at the
plasma membrane
14 μM
CytoD Blocks actin polymerisation by occupying fast
growing end of ﬁlament
5 μM, 10 μ
DMA Na+/H+ ion exchange inhibitor 50 μM, 10
Dynasore Dynamin GTPase inhibitor 40 μM, 80
EIPA Na+/H+ ion exchange inhibitor 25 μM, 50
Genistein Tyrosine kinase inhibitor 92.5 μM
Gö 6976 Protein kinase C inhibitor (α and β1 isoforms) 0.5 μM, 1
H1152 Rho-associated kinase inhibitor 20 μM, 40
HMA Na+/H+ ion exchange inhibitor 6.25 μM, 1
IPA-3 Inhibits p21 associated kinase-1 (Pak1) 20 μM
Jasp stabilises F-actin by stimulating actin ﬁlament
nucleation
1 μM, 2 μM
LatA Binds actin monomers preventing incorporation
into ﬁlaments
1 μM, 2 μM
LY294002 PI-3 kinase inhibitor 50 μM, 10
NSC23766 Rho GTPase Rac inhibitor 50 μM, 10
Wiskostatin N-WASP inhibitor 10 μM
Wortmannin PI-3 kinase inhibitor 20 nM–30
Y-27632 Rho-associated kinase inhibitor 40 μM, 80
a Cell viability measured using CellTiter 96® AQueous One Solution Cell Proliferation Assof drug. Quantiﬁcation of HIV BaL late reverse transcripts 28 h p.i.
showed that DMA, at both concentrations tested and from multiple
batches, does not signiﬁcantly inhibit virus reverse transcription in
macrophages derived from 7 donors (Fig. 2C). However, when we
measured the supernatant levels of p24 released from infected cells
over multiple rounds of infection we found that DMA reduced p24
release in macrophages from all 3 donors tested (Fig. 2D, 2 donors are
shown). A second amiloride, HMA, also did not affect HIV-1 entry at
12.5 μM (data not shown). We then tested a third amiloride
derivative, EIPA, which at non-toxic concentrations of 50 and 25 μM
signiﬁcantly reduced reverse transcription in infected cells by about
3-fold and 2-fold respectively (Fig. 2E).
The amiloride derivatives tested here had contrasting effects on
HIV entry, so we veriﬁed if the drugs were blocking macropinocytosis
by measuring the uptake of 70 kDa Dex-TR, a standard ﬂuid phase
marker of macropinocytosis. Drug-treated macrophages were incu-
bated with Dex-TR for 30 min at 37 °C and the amount of cell-
associated Texas Red ﬂuorescence was measured using ﬂow cyto-
metry. 70 kDa Dextran uptake was not signiﬁcantly inhibited by
100 μM DMA (Fig. 2F), nor by 12.5 μMHMA (data not shown). Higher
molecular weight dextran has also been used to study macropinocy-
tosis in macrophages (Araki et al., 1996; Ghigo et al., 2008), so we
tested the effect of DMA on 150 kDa Dex-FITC uptake. DMA
signiﬁcantly inhibited 150 kDa Dex-FITC by 1.5 fold (Fig. 2F), however
in comparison, 50 μM EIPA had a much more potent effect. EIPA
inhibited uptake of 70 kDa Dex-TR by 2-fold and very signiﬁcantly
inhibited the uptake of 150 kDa Dex-FITC (Fig. 2F). Therefore, it is
likely that EIPA has a stronger effect on ﬂuid phase uptake in
macrophages and this may explain the contrasting effects that
amilorides have on HIV entry and it is consistent with a macro-
pinocytosis route of entry.
A dynamic actin cytoskeleton is required for HIV-1 entry into macrophages
Macropinosome formation is strictly dependent on actin. Upon
stimulation, actin polymerisation near the plasma membrane results
in the formation of actin-rich extensions called membrane rufﬂes;
macropinosomes are formed when these rufﬂes fold back and fuse
with plasma membrane and in doing so entrap extracellular ﬂuidoxic concentrations
udy
Cytotoxic concentration Incubation time
μM 2 μM 1 h prior+1.5 h during
0 μM 200 μM 1 h prior+1.5 h during
100 ng/mL 200 ng/mL 1 h prior
28 μM 1 h prior+1.5 h during
M 20 μM 1 h prior
0 μM 200 μM 1 h prior
μM 160 μM 1 h prior+1.5 h during
μM 100 μM 1 h prior
300 μM 1 h prior+1.5 h during
μM No toxicity seen up to 10 μM 1 h prior+1.5 h during
μM 300 μM 1 h prior+1.5 h during
2.5 μM 50 μM 1 h prior+1.5 h during
40 μM 1 h prior+1.5 h during
4 μM 1 h prior
4 μM 1 h prior
0 μM 200 μM 1 h prior+1.5 h during
0 μM 200 μM 1 h prior+1.5 h during
20 μM 1 h prior+1.5 h during
0 nM 500 nM 1 h prior+1.5 h during
μM 160 μM 1 h prior+1.5 h during
ay reagent.
Fig. 3. Dynamic actin rearrangements are required for HIV entry into macrophages.
(A) Productive HIV entry into macrophages treated for 1 h with cytoD, latA and jasp
was measured at 28 h p.i. by qPCR. (B) Inhibition of macropinocytosis was measured by
detecting the uptake of 70 kDa Dex-TR in drug-treated cells for 30 min at 37 °C by ﬂow
cytometry. Background binding of the markers to untreated cells at 4 °C was used as a
control and subtracted from all 37 °C samples. (C) The surface expression of HIV
receptors after cytoD, latA and jasp treatment was determined by staining
macrophages with ﬂuorescent monoclonal antibodies to CD4, CCR5 or an appropriate
isotype control and cell surface binding was measured by ﬂow cytometry. Data
represent mean±SD of results obtained with multiple independent experiments using
cells from several donors (number of donors used for qPCR and dextran uptake is
stated, 4–5 donors for receptor ﬂow cytometry). ns — non-signiﬁcant, *signiﬁcant
difference pb0.05, **very signiﬁcant difference pb0.01 and ***extremely signiﬁcant
difference pb0.001 (one sample t-test).
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as cytoD and latA are commonly used to block macropinocytosis
(Dharmawardhane et al., 2000). Macrophages treated with non-toxic
concentrations of these drugs (Table 1) for 1 h were challenged with
HIV BaL for 90 min in the absence of drug. Both cytoD and latA, at the
highest concentrations tested, signiﬁcantly inhibited HIV reverse
transcription by 2-fold and about 8-fold, respectively (Fig. 3A). Jasp is
an actin stabilising drug. Treatment of macrophages with this
inhibitor resulted in signiﬁcant reduction of reverse transcripts by
over 8-fold at the highest concentration tested (Fig. 3A). All of these
drugs have an inhibitory effect on macropinocytosis and caused a
signiﬁcant reduction in the uptake of 70 kDa Dex-TR in macrophages
(Fig. 3B). We thought it necessary to rule out the possibility that
decreased HIV entry was the result of alterations in receptor or co-
receptor levels because a dynamic actin cytoskeleton is required for
receptor clustering and movement (Iyengar et al., 1998). Accordingly,
we tested whether macrophages treated with these drugs had altered
levels of CD4 and CCR5 by labelling the cell surface with ﬂuorescent
antibodies and detecting by ﬂow cytometry. Treatment of macro-
phages with cytoD, latA and jasp did not signiﬁcantly decrease CD4 or
CCR5 surface expression levels (Fig. 3C). Therefore, the decreased HIV
entry observed in macrophages with a disrupted actin cytoskeleton
may result from the reduced macropinocytosis or similar actin-
dependent endocytosis but not from altered HIV receptor levels.
HIV-1 entry into macrophages is partially inhibited by inhibitors of
macropinocytosis signalling
The effects of actin depolymerising drugs and amiloride com-
pounds are not solely the inhibition of macropinocytosis. However
there are other pharmacological inhibitors targeting key regulators of
actin that also efﬁciently inhibit macropinocytosis. To determine
whether this pathway is involved in HIV entry, we selected a number
of these inhibitors for use in our qPCR assays of virus reverse
transcription. We started with LY294002, a compound that prevents
the closure of cup-shaped circular rufﬂes into macropinosomes by
inhibiting PI-3 kinase (Araki et al., 1996). LY294002 is relatively
selective for PI-3 kinase although it also inhibits casein kinase 2 with
similar potency in an in vitro assay (Davies et al., 2000), as well as
phosphorylase kinase with lower potency. HIV reverse transcription
was not signiﬁcantly inhibited in macrophages treated with non-toxic
concentrations of LY294002, and instead an enhancing trend was
observed (Fig. 4A). This effect was also seen at numerous other
concentrations of drug (from several batches), with cells from
multiple donors (data not shown). As the drug treatment is
terminated following spinoculation, a lack of effect could be attributed
to virus entry during the 28-hour period following drug removal if the
effects are reversible. To demonstrate that this was not the case, we
added the HIV-1 fusion inhibitor T-20 to the medium following the
removal of inoculum and drug; T-20 is a peptide that binds to gp41 on
receptor engagement, preventing a further conformational change
that is necessary for fusion (Wild et al., 1994). T-20 reduced the
number of copies seen per cell, however we were still able to detect a
measurable level of infection (Fig. 4A). Comparing control cells with
LY294002 treated cells when both are treated with T-20, there is no
signiﬁcant effect of drug treatment (Fig. 4A), consistent with our
ﬁndings in the absence of T-20. Interestingly, LY294002 signiﬁcantly
inhibited the uptake of 70 kDa Dex-TR by 1.5-fold and 150 kDa Dex-
FITC by about 3 fold (Fig. 4A); therefore this drug has the expected
effect on macropinocytosis in macrophages.
To conﬁrm that PI-3 kinase is not required for macrophage HIV-1
entry, we tested another PI-3 kinase inhibitor, wortmannin. This
compound is a highly potent and selective PI-3 kinase inhibitor (Davies
et al., 2000). Multiple doses of this drug show no signiﬁcant effect on
HIV-1 reverse transcription, and an enhancing trend similar to that seen
with LY294002 was observed (data not shown). We were not able toshow a signiﬁcant effect of wortmannin on uptake of either 70 kDa
Dex-TR or 150 kDa Dex-150, but an inhibitory trend was observed
(data not shown). Taken together, our results with LY294002 and
A PI-3 kinase
C Rac D Rho kinase
B Rho family GTPases
E N-WASP F Pak1 G Myosin II
H PKC
n=3 n=3 n=3 n=3 n=8 n=4
ns * ns ns *** ***
100 M 50 M 100 M 50 M 50 M 80 M
LY294002
Without T-20 With T-20
HIV copies HIV copies
70 kDa
Dex
uptake
150 kDa
Dex
uptake
0
100
25
50
75
125
150
DMSO
Control
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
n=4 n=4 n=3
*** * *
Control 100 M 50 M 100 M
NSC
HIV copies 70 kDa Dex
uptake
0
100
10
20
30
40
50
60
70
80
90
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
n=3 n=3 n=3 n=3 n=5 n=3
ns * ns ns * ns ns
Control 80 M 40 M 80 M 40 M 80 M 40 M 20 M
Y-27632
Without T-20
HIV copies
With T-20
HIV copies
70 kDa
Dex
uptake
HIV copies
H1152
0
20
40
60
80
100
120
140
160
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
n=5
* **
DMSO 10 M 10 M
Control
Wisko
HIV
copies
70 kDa
Dex
uptake
0
100
10
20
30
40
50
60
70
80
90
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
ns ns ns
DMSO 100 M 50 M 100 M
Control
Bleb
HIV copies 70 kDa
Dex
uptake
n=5
0
50
25
75
100
125
150
175
200
225
n=5
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
n=5
*** *
DMSO 20 M 20 M
Control
IPA-3
HIV
copies
70 kDa
Dex
uptake
100
0
10
20
30
40
50
60
70
80
90
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
C. diff. Toxin B
n=5
*** *
0
100
10
20
30
40
50
60
70
80
90
DMSO 100 ng/ml 50 ng/ml
Control
Pe
rc
en
ta
ge
o
fc
o
pi
es
/c
el
l
co
m
pa
re
d
to
co
n
tr
o
l
* ns ns
DMSO 1 M 0.5 M 1 M
Control
Gö 6976
HIV copies 70 kDa
Dex
uptake
n=5 n=5
0
100
150
200
250
50
300
350
400
Pe
rc
en
ta
ge
co
m
pa
re
d
to
co
n
tr
o
l
240 G.C. Carter et al. / Virology 409 (2011) 234–250
241G.C. Carter et al. / Virology 409 (2011) 234–250wortmannin imply that HIV entry does not require PI-3kinase and
therefore does not proceed by traditional macropinocytosis.
Src-family kinases are also involved in macropinocytosis (Kasahara
et al., 2007); we tested whether the broad tyrosine kinase inhibitor
genistein could affect HIV-1 entry and Dex-TR uptake. In agreement
with others (Stantchev et al., 2007), HIV entry was signiﬁcantly
inhibited by a 92.5 μM treatment, and 70 kDa Dex-TR uptake was also
reduced (data not shown).
Actin polymerisation is controlled by signal transduction path-
ways orchestrated by the Rho family GTPases, such as Rac, Rho and
Cdc42 (Ladwein and Rottner, 2008). These GTPases can be activated
downstream of PI-3 kinase activity (Welch et al., 2003). Activated Rac
mediates the formation of lamellipodia and membrane rufﬂes (thin
protrusions), activated Rho regulates the formation of stress ﬁbres
(stiff actin bundles forming focal adhesions) and Cdc42 induces the
formation of ﬁlopodia (ﬁnger-like projections) (Hall, 2005; Ladwein
and Rottner, 2008). Actin rearrangements required for macropinocy-
tosis are driven by activated Rac through its stimulation of membrane
rufﬂing and lamellipodia (West et al., 2000). We investigated the role
of Rho family GTPases and speciﬁcally Rac on HIV entry in
macrophages. Macrophages were exposed to Clostridium difﬁcile
Toxin B, which glycosylates Rac, Rho and Cdc42 and inhibits their
functions, for 1 h prior to infection with HIV BaL. HIV reverse
transcription was signiﬁcantly inhibited by about 6-fold at 100 μg/
mL, the highest non-toxic concentration tested (Fig. 4B). Therefore,
HIV entry into macrophages is dependent on signalling by the Rho
family GTPases. To test the requirement for Rac, Rho and Cdc42
individually we used drugs that either directly perturb the function of
these proteins or inhibit downstream signalling events triggered by
them. Treatment of macrophages with 100 μM NSC23766, a speciﬁc,
rationally designed Rac inhibitor that does not affect the function of
Rho or Cdc42 (Gao et al., 2004), signiﬁcantly decreased both virus
reverse transcripts and 70 kDa dextran uptake by approximately 2-
fold (Fig. 4C). Inhibitors of Rho and Cdc42 are not commercially
available so we used inhibitors targeting molecules downstream in
their signalling pathways. One downstream protein of Rho is the Rho
kinase ROCK1, a serine/threonine kinase whose activation leads to the
formation of focal adhesions and stress ﬁbres resulting in cytoskeletal
rearrangements (Leung et al., 1996).We treatedmacrophages with an
inhibitor of ROCKI/II, Y-27632 (Narumiya et al., 2000) and found that
inhibition of ROCK signalling had no effect on HIV BaL reverse
transcription (Fig. 4D), although dextran uptakewas reduced.We also
tested this inhibitor with the addition of T-20 following infection, to
prevent virus entry from taking place following removal of drug. No
inhibition of infection was seenwith T-20 addition when compared to
untreated cells (Fig. 4D). To conﬁrm this ﬁnding we tested a second,
more potent and speciﬁc, ROCK inhibitor H1152 (Ikenoya et al., 2002),
which also had no effect on HIV-1 infection (Fig. 4D). Again, we
observe with Y-27632 that treatment of macrophages with agents
inhibiting macropinocytosis does not correlate with a reduction in
HIV entry. This provides more evidence that macropinocytosis is not
the productive route for entry.
Cdc42 activates the haematopoietic and neural Wiskott-Aldrich
syndrome protein (N-WASP) and Arp2/3 complex to stimulate actin
polymerisation. N-WASP is not essential for Rac-dependent mem-
brane protrusions and macropinocytosis (Innocenti et al., 2005)
although it does have roles in Fc-gamma receptor-mediated phago-Fig. 4. Cellular signalling involving Rac GTPase and Pak1 is required for virus entry. Productiv
events was measured by qPCR detection of reverse transcription products 28 h p.i. Inhibit
150 kDa Dex-FITC in drug-treated cells for 30 min at 37 °C, by ﬂow cytometry. Background bi
all 37 °C samples. Cells were treated with (A) LY294002 (PI-3 kinase inhibitor), (B) C. diff. To
and H1152 (ROCK inhibitors), (E) wiskostatin (N-WASP inhibitor), (F) IPA-3 (Pak1 inhibit
prevent infection occurring following drug removal, T-20 fusion inhibitor was added in som
represent mean±SD of results obtained withmultiple independent experiments with cells fr
difference pb0.01 and ***extremely signiﬁcant difference pb0.001 (one sample t-test).cytosis (Park and Cox, 2009). If HIV enters macrophages by classical
macropinocytosis, an inhibitor of N-WASP, wiskostatin (Peterson
et al., 2001), should have no effect on HIV entry. Macrophages treated
with wiskostatin had a signiﬁcant reduction in HIV entry by over 2-
fold and a signiﬁcant reduction in dextran uptake (Fig. 4E). However
wiskostatin may have more global effects on cells in addition to
inhibiting N-WASP; it is reported that it causes a rapid drop in cellular
ATP levels which non-selectively perturbs membrane transport
events (Guerriero and Weisz, 2007).
Rac and Cdc42 are speciﬁc regulators of Pak1, and this serine
threonine kinase has been heavily implicated in macropinocytosis
with roles in all stages (Dharmawardhane et al., 2000; Mercer and
Helenius, 2009). To determine the role of Pak1 in HIV entry into
macrophages we inhibited the action of this kinase by using a highly
speciﬁc inhibitor, IPA-3 (Deacon et al., 2008). Reverse transcripts in
IPA-3 treated macrophages were signiﬁcantly reduced compared to
control cells and at the highest non-toxic concentration tested we
observed a 4-fold decrease (Fig. 4F). Dextran uptake was also
signiﬁcantly inhibited by IPA-3 treatment by almost 1.5-fold
(Fig. 4F). Therefore we can conclude that HIV entry into macrophages
requires Rac, and the stimulation of Pak1 activity. Rho-mediated
signalling through ROCK1 is not required but WASP-mediated actin
rearrangements may be needed. There may also be a role for Cdc42,
however it was not possible to test this directly as there is not a
commercially available inhibitor, and although we actively sought to
obtain the published inhibitor secramine A from other researchers, we
were unsuccessful.
Myosins are present in the membrane rufﬂes and through Pak1
signalling they provide contractile activity for macropinosome
closure. Membrane rufﬂes can take three forms: planar folds known
as lamellipodia, circular cup-shaped rufﬂes and large plasma
membrane extrusions called blebs (Mercer and Helenius, 2009).
These actin-containing blebs are stimulated upon vaccinia virus
infection, and their retraction into the plasma membrane mediates
virus entry (Mercer and Helenius, 2008). Inhibition of non-muscle
myosin II is reported to prevent rufﬂe curvature, closure and
membrane blebs. Although live visualisation of HIV entry into
macrophages has never been accomplished and the existence of
membrane blebs in human macrophages is unknown, we decided to
inhibit myosin II function and membrane blebbing using blebbistatin,
a small molecule inhibitor which prevents the interaction of actin
with myosin II and is thought to be highly speciﬁc for its target
(Kovacs et al., 2004). Blebbistatin treatment of macrophages caused
no signiﬁcant decrease in viral reverse transcripts or dextran uptake
(Fig. 4G). Therefore, neither HIV entry nor macropinocytosis of
dextran in macrophages require membrane blebbing or myosin II
dependent contractile activity.
Protein kinase C (PKC) is involved in macropinocytosis, playing a
key role signalling processes leading to membrane rufﬂing, (Amyere
et al., 2000; Miyata et al., 1989). PKC is also thought to contribute to
caveolar endocytosis (Doherty and McMahon, 2009; Parton and
Simons, 2007) and to phagocytosis (Swanson and Hoppe, 2004). We
inhibited PKC using a small molecule inhibitor Gö 6976, which is a
competitive inhibitor of ATP binding to PKC isoforms α and β1
(Martiny-Baron et al., 1993), and is largely speciﬁc for its target at the
concentrations used (Qatsha et al., 1993). With 1 μM Gö 6976, we
observed a signiﬁcant 3-fold enhancement of HIV-1 infectione HIV-1 BaL entry into macrophages pre-treated with drugs inhibiting various signalling
ion of macropinocytosis was measured by detecting the uptake of 70 kDa Dex-TR or
nding of themarkers to untreated cells at 4 °C was used as a control and subtracted from
xin B (broad Rho family GTPase inhibitor), (C) NSC23766 (Rac inhibitor), (D) Y-27632
or), (G) blebbistatin (myosin II inhibitor) and (H) Gö 6976 PKC inhibitor. In order to
e cases following spinoculation in the presence of (A) LY294002 and (D) Y-27632. Data
om 3 to 8 donors. ns— non-signiﬁcant, *Signiﬁcant difference pb0.05, **very signiﬁcant
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70 kDa Dex-TR.
Dynamin GTPase is required for HIV-1 macrophage entry
Dynamin is small cytosolic GTPase that plays a crucial role in
pinching off or scission of internalized clathrin-coated vesicles,
caveolae, Golgi complex-derived vesicles, non-clathrin-coated endo-
somes and phagosomes. Macropinocytosis does not generally require
dynamin (Meier et al., 2002); the mouse macrophage cell line RAW
264.7 transfected with the dominant negative dynamin K44A
internalized dextran in a similar way to cells with functional dynamin
(Ghigo et al., 2008). Much evidence shows that C-terminal-binding
protein-1/brefeldin A-ADP ribosylated substrate (CtBP1/BARS) may
substitute for dynamin during macropinocytosis by facilitating fusion
of the macropinosome neck (Liberali et al., 2008). We investigated a
role for dynamin GTPase in HIV entry into macrophages by using a
cell-permeable inhibitor of dynamin I and II known as dynasore,
which is thought to be highly speciﬁc for its target (Macia et al., 2006).
We treated macrophages with the recommended working concentra-
tions of dynasore, 80 and 40 μM, which proved to be non-toxic and
inhibited transferrin-488 uptake (Fig. 5C), although this was variable
and did not reach signiﬁcance (suggesting that transferrin may be
taken up through several pathways in primary macrophages). HIV
reverse transcription was signiﬁcantly reduced by about 3.5-fold with
80 μM and over 2-fold with 40 μM (Fig. 5A), demonstrating that HIV
entry in macrophages is dependent on dynamin GTPase. We tested
whether dynamin activity is required for macropinocytosis in our
macrophages. Surprisingly, we found that the uptake of 70 kDa Dex-
TRwas signiﬁcantly reduced inmacrophages with perturbed dynamin
function (Fig. 5D). Dynasore treatment led to over a 4-fold reduction
in dextran uptake, the highest level of inhibition observed with any of
the inhibitors tested here. Therefore, dynamin is crucial for both HIV
entry and dextran uptake in macrophages. Dynamin's involvement in
many endocytic uptake pathways may alter HIV receptor expression
levels so we checked the levels of CD4 and CCR5 to establish if this
might contribute to the reduction in HIV entry. The cell surface
expression levels of CD4 and CCR5 were unaltered by dynasore
treatment (Fig. 5E).
As dynamin is essential for clathrin-mediated endocytosis, we also
wanted to check whether clathrin was required for HIV-1 entry in
macrophages. Chlorpromazine is a drug which prevents clathrin
lattices from assembling at the plasma membrane but causes their
assembly on endosomal membranes, likely through affecting AP-2
binding (Wang et al., 1993). Treatment of macrophages with 14 μM
chlorpromazine did not affect HIV-1 reverse transcription (Fig. 5A)
but did signiﬁcantly inhibit transferrin uptake (Fig. 5C), a protein that
is internalized through clathrin-mediated endocytosis (Doherty and
McMahon, 2009). Chlorpromazine did not signiﬁcantly affect 70 kDa
Dex-TR uptake (Fig. 5D) as expected.
Macropinocytic vesicles can become acidiﬁed and intersect with
endocytic vesicles. We investigated a requirement for vesicle
acidiﬁcation by using a speciﬁc and potent inhibitor of vacuolar H+-
ATPase, bafA. When macrophages were treated with 1 μM and 0.5 μM
bafA prior to and during infection, reverse transcription was not
inhibited, and conversely at 0.5 μM a signiﬁcant enhancement by over
1.5-fold was observed (Fig. 5A). Furthermore this enhancement was
exhibited when virus production was measured over multiple rounds
of infection, with increased levels of p24 being released from infected
cells for the duration of the experiment (Fig. 5B, 2 donors are shown).
Dextran uptake was signiﬁcantly inhibited in bafA treated macro-
phages by about 2.5-fold (Fig. 5D) but receptors remained unaltered
(Fig. 5E). Therefore, HIV entry into macrophages is pH-independent
and does not require vesicle acidiﬁcation. Inhibition of vesicle
acidiﬁcation enhances HIV entry and this is in agreement with other
reports that elevation of endosomal and lysosomal pH allows HIV toenter cell lines with increased efﬁciency (Fredericksen et al., 2002;
Schaeffer et al., 2004;Wei et al., 2005). Again, we observe discordance
between HIV entry and dextran uptake showing that HIV entry is not
mediated through the same pathway as dextran internalization.
Discussion
The results presented in this study elucidate some of the cellular
factors required for the successful entry and reverse transcription of
HIV in macrophages. Following on from our previous study, in which
we demonstrated the importance of cholesterol and lipid rafts for
virus entry, we asked whether lipid raft-dependent caveolae were
involved. Cav-1, the main structural and driving component of
caveolae, is present in macrophages derived from other species and
in human cell lines (Arakawa et al., 2000; Baorto et al., 1997;
Gargalovic and Dory, 2001; Harris et al., 2002a; Kiss et al., 2000; Lei
and Morrison, 2000). However, no conclusive study into cav-1
expression in any human leukocyte has been performed, although
one report using confocal microscopy indicates cav-1 expression in
human macrophages (Ueno et al., 2009). Surprisingly, we ﬁnd that
cav-1 and cav-2 are not expressed in human monocytes, macro-
phages, DCs nor CD4+ T lymphocytes even after differentiation,
activation or maturation. The absence of cav-1 and -2 implies the
absence of caveolae in human peripheral blood cells, and hence that
HIV entry does not proceed by this pathway.
Cholesterol-dependent, non-caveolar pathways are responsible
for the uptake of SV40 virions, Cholera Toxin B, GM1 ganglioside,
glycosylphosphatidylinositol (GPI)-linked proteins, glycosamino-
glycans and IL-2 receptor, among others (reviewed in Doherty
and McMahon, 2009). These pathways include the GPI-anchor
protein enriched early endosomal compartments (GEEC) pathway
(Sabharanjak et al., 2002), the ﬂotillin pathway, (Frick et al., 2007;
Glebov et al., 2006; Langhorst et al., 2008), and macropinocytosis
(Grimmer et al., 2002). Of these, macropinocytosis has been
implicated by one study on the entry of HIV into primary
macrophages (Marechal et al., 2001). Since this original study, the
cellular molecules and signalling events involved in macropinocy-
tosis have been further elucidated, and reveal that it is more
complex than ﬁrst thought. Many more viruses have been found to
use this endocytic route for entry, and through these studies a
comprehensive list of requirements for virus uptake by macro-
pinocytosis has been established (Mercer and Helenius, 2009). We
have found that visualising the early events of HIV infection of
macrophages by microscopy is challenging because both Env-
positive and Env-negative virus particles co-localise with ﬂuid
phase markers of macropinocytosis (70 kDa Dex-TR), and this lack
of speciﬁcity is in agreement with others (Marechal et al., 2001;
Trujillo et al., 2007).
Therefore, we adopted a pharmacological approach using inhibi-
tors that interfere with macropinocytosis, and determined their effect
on productive HIV entry by detecting late reverse transcripts using
qPCR. Table 2 summarises these results and compares them with
published data concerning other characterised pathways and our own
data on macropinocytosis, as measured by dextran uptake. In
summary, we found that HIV entry into macrophages was sensitive
to inhibitors of Na+/H+ exchange, actin rearrangements, Rho GTPases
including Rac but not Rho, N-WASP, Pak1 and dynamin GTPase.
Conversely, inhibitors of PI-3 kinase, Rho kinase, myosin II, and
clathrin assembly had no effect on HIV entry, and inhibitors of vesicle
acidiﬁcation and PKC enhanced HIV entry. Whilst many of these
cellular factors ﬁt the experimental criteria for macropinocytosis,
there are a number of important molecules, such as PI-3 kinases,
whose dispensability leads us to believe that HIV does not enter
macrophages by macropinocytosis, as it is generally understood.
Furthermore, some of these compounds, including inhibitors of PI-3
kinases, ROCK1 and vesicle acidiﬁcation, reduced the macropinocytic
243G.C. Carter et al. / Virology 409 (2011) 234–250uptake of dextran but did not inhibit HIV entry. This leads us to
believe that HIV entry and dextran uptake, although they share some
common requirements, proceed by separate pathways and that HIV
entry into macrophages occurs via a novel endocytic route, which weFig. 5. Dynamin GTPase but not vesicle acidiﬁcation or clathrin is required for HIV entry in
macrophages was measured at 28 h p.i. by qPCR as before. (B) HIV-1 BaL infection following
(collected regularly from 1 to 15 days p.i.) by p24 ELISA. (C) Inhibition of clathrin-depende
drug-treated cells for 30 min at 37 °C by ﬂow cytometry. Background binding of transferrin-4
(D) Inhibition of macropinocytosis was measured by detecting the uptake of 70 kDa Dex-T
expression of HIV receptors after bafA and dynasore treatment was determined by staining
isotype control. Cell surface binding was measured by ﬂow cytometry, and mean ﬂuorescenc
speciﬁc antibody ﬂuorescence. Data represent mean±SD of results obtained with multiple
cytometry, and p24 data shows 2 donors but is representative of 3). ns — non-signiﬁcant
signiﬁcant difference pb0.001 (one sample t-test).provisionally term a Pathway of HIV Endocytic Entry in Macrophages
(PHEEM).
Both PHEEM and macropinocytosis share a requirement for
dynamic actin rearrangements, which are not characteristic of othermacrophages. (A) Productive HIV entry in dynasore, chlorpromazine, and bafA treated
bafA treatment was measured by detecting released virus in the supernatant samples
nt endocytosis was measured by detecting the uptake of ﬂuorescent transferrin-488 in
88 to untreated cells at 4 °C was used as a control and subtracted from all 37 °C samples.
R in drug-treated cells for 30 min at 37 °C by ﬂow cytometry as above. (E) The surface
macrophages with ﬂuorescent monoclonal antibodies to CD4, CCR5 or an appropriate
e intensity values were calculated by subtracting the isotype control ﬂuorescence from
independent experiments using cells from several donors (6 donors for receptor ﬂow
, *signiﬁcant difference pb0.05, **very signiﬁcant difference pb0.01 and ***extremely
244 G.C. Carter et al. / Virology 409 (2011) 234–250endocytotic pathways. CytoD and latA, two inhibitors commonly
used to disassemble actin, and jasp, an actin stabilising drug, all
signiﬁcantly inhibited HIV entry and dextran uptake in macrophages.
In macropinocytosis, actin is needed for the dynamics of membrane
rufﬂes, but it is known to have other roles in HIV infection, including
the clustering of viral receptors upon HIV envelope binding in
lymphocytic cell lines (Iyengar et al., 1998; Lu et al., 2008). Our data
do not exclude a role for actin in either rufﬂing or receptor clustering
during PHEEM. However, we show that Rho kinase inhibitors, which
would block the RhoA/ﬁlamin A-mediated actin-dependent clustering
of HIV-1 receptors described in Jurkat cell infection by X4 enveloped
HIV-1 (Jimenez-Baranda et al., 2007), have no effect on R5 entry in
primary macrophages. Conversely, we show that inhibition of the
related Rac GTPase, or its effector kinase Pak1, which can also affect
actin remodelling through the ﬁlamin-A/Lim kinase/coﬁlin pathway,
does block infection of macrophages by HIV, whereas this signalling
pathway is not involved in the infection of cell lines by X4 virus
(Jimenez-Baranda et al., 2007). Interestingly, HIV-1 Env-mediated
membrane fusion in HeLa and U87 cells also depends on Rac but not
Rho-mediated actin rearrangements (Harmon and Ratner, 2008;
Pontow et al., 2004), suggesting that HIV entry in macrophages may
share features with the process seen in receptor-transfected, non-
lymphoid cells. One hint that the requirement for actin remodelling in
PHEEM might not relate to membrane rufﬂing is our ﬁnding that
inhibition of myosin II, which is required for the formation and
resolution of rufﬂes (Dowrick et al., 1993) using the drug blebbistatin,
does not inhibit HIV entry into macrophages.
The clearest distinction between macropinocytosis and PHEEM lies
their differential requirement for PI-3 kinase (Araki et al., 1996). Others
have reported that the PI-3 kinase inhibitor, LY294002, decreased JRFL
pseudotyped HIV-1 virus infection of both macrophages and CD4+ T
cells by 75% (Francois and Klotman, 2003), consistent with the
involvement of macropinocytosis in infection. However, as the
conclusion was based on effects on virus-encoded luciferase, and their
own semi-quantitative PCR assay of reverse transcription detected noTable 2
Comparison of HIV-1 entry requirements with known endocytic pathways.
Pathway
component
(inhibitor)
HIV entry into
macrophages
(this and other
studies)
HIV entry into
lymphocytes/
cell lines
Dextran uptake
(this study)
Macropinocy
Na+/H+ ion
exchanger
(EIPA) ✓ ? ✓ ?
(DMA) ✕ ✕3 ✕ ✓4,5
Actin polymerisation
(cytoD/latA/jasp)
✓ ✓6 ✓ ✓7
Dynamin (dynasore) ✓ ✓11 ✓ ✕ 1
Myosin II (Bleb) ✕ ? ✕ ✓14,15
PI-3 kinase
(LY294002)
✕16 ✓16 ✓ ✓17
Tyrosine kinases
(genistein)
✓ ✓ ? ✓19
Rac1 (NSC23766) ✓ ✓22,26 ✓ ✓24,25
✕23
RhoA/Rho-associated
kinase (Y-27632,
H1152)
✕ ✓23 ✓ ?
✕22,26
Cdc42 ? ✕22,26 ? ✓27,28
N-WASP (wisko) ✓ ? ✓ ✕29
Pak1 (IPA-3) ✓ ✓32 ✓ ✓10
✕23
Protein kinase C
(Gö 6976)
✕ ? ✕ ✓33,34
Vesicle acidiﬁcation
(bafA)
✕ ✕36,37,38 ✓ ✓b,39
Clathrin assembly
(chlor)
✕ ✓41,11 ✕ ✕1inhibition by LY294002, this probably indicates that PI-3 kinase is
involved in a late stage of the virus life cycle, rather than entry.
Most interestingly, we ﬁnd that HIV entry into macrophages is
dynamin-dependent. While this is consistent with reports that HIV
entry in lymphocytes and immortalized cell lines requires dynamin
(Miyauchi et al., 2009), it is not consistent with macropinocytosis,
as documented for toher viruses such as vaccinia virus (Mercer and
Helenius, 2008), adenovirus 3 (Amstutz et al., 2008), coxsackievirus B
(Coyne et al., 2007), echovirus-1 (Karjalainen et al., 2008), Kaposi's
sarcoma herpesvirus (Raghu et al., 2009) and Ebola virus (Nanbo
et al., 2010; Saeed et al., 2010).
We also ﬁnd that dextran uptake is inhibited by dynasore, and this
is in disagreement with others, who found that 50 kDa Dex-TR uptake
was not inhibited by the expression of dominant negative dynamin II
constructs in the RAW 264.7 mousemacrophage cell line (Ghigo et al.,
2008). However, it is possible that 70 kDa Dex-TR may enter our
macrophages through a Rac-dependent PDGF-induced form of
macropinocytosis which is known to require dynamin (Schlunck
et al., 2004). It is also possible that dextran internalization can occur
through more than one pathway in these cells, or that macropinocy-
tosis is different in primary macrophages compared to cell lines that
do not constitutively macropinocytose.
Some of our data appear, at ﬁrst, to conﬂict with those of others,
and require further comment. Unlike Marechal et al. (2001), we do
not ﬁnd that inhibition of Na+/H+ exchangers with the amiloride,
DMA, inhibits either HIV entry or macropinocytosis in macrophages,
although EIPA, a more speciﬁc inhibitor does in our hands. Our ﬁnding
is broadly in line with the conclusion that Na+/H+ exchangers
are required for macropinocytosis and related internalization path-
ways, through the induction of membrane rufﬂes by either raising
cytosol pH or actin modulation (Dowrick et al., 1993; Norbury et al.,
1995). The lack of effect of DMA in our hands may result from the
known upregulation of macropinocytosis in macrophages by M-CSF
(Racoosin and Swanson, 1989; Racoosin and Swanson, 1992; Smith
et al., 1998), rendering our cells more refractory to DMA-mediatedtosis Clathrin-
mediated1
Caveolae
mediated1,2
CLIC/
GEEC1
Flotillin
mediated1
IL2Rβ
uptake1
Arf6
dependent1
Phago-
cytosis1
? ? ? ? ? ? ?
✕ ✕ ✕ ✕ ✕ ✕ ✕
✓a,8 ✓ ✓9 ? ✓10 ✓ ✓
✓ ✓ ✕ ?✓12 ✓13 ✕ ✓
? ? ? ? ? ? ✓15
✕17 ? ? ? ? ? ✓18
✓20 ✓ ? ✓13,21 ? ? ✓
✕10 ? ? ? ✓13 ? ✓
✕ ? ? ? ✓13 ? ✓
✕ ✓? ✓9 ✕12 ? ? ✓
✓30 ? ✓9 ? ? ? ✓31
✕10 ? ? ? ✓10 ? ?
✕ ✓2 ? ? ? ? ✓35
✓b ✕ ? ? ✓ ✕ ✓40
✓1 ✕1 ✕ ✕ ✕ ✕ ✕
Notes to Table 2:
✓=evidence of involvement in pathway, ✕=evidence that this component is not required, ?=component not speciﬁcally tested for involvement. Studies referred to are either
based on the use of pharmacological inhibitors or dominant negative proteins.
1 Doherty, G. J., and McMahon, H. T. (2009). Mechanisms of endocytosis. Annu Rev Biochem 78, 857-902.
2 Parton, R. G., and Simons, K. (2007). The multiple faces of caveolae. Nat Rev Mol Cell Biol 8(3), 185-94.
3 Marechal, V., Prevost, M. C., Petit, C., Perret, E., Heard, J. M., and Schwartz, O. (2001). Human immunodeﬁciency virus type 1 entry into macrophages mediated bymacropinocytosis.
J Virol 75(22), 11166-77.
4 Dowrick, P., Kenworthy, P., McCann, B., andWarn, R. (1993). Circular rufﬂe formation and closure lead to macropinocytosis in hepatocyte growth factor/scatter factor-treated cells.
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virus replication assay, which measures multiple rounds of infection.
But this may have resulted from a known off-target effect of DMA,
inhibition of the viral vpu ion channel (Ewart et al., 2004).
We fully acknowledge that our results must be interpreted with
some caution, because of the methodological restrictions imposed by
our determination only to use authentic primarymacrophages for this
study, rather than immortalized cell lines that have some macro-
phage-like properties. The pharmacological approach we have taken
has the potential to generate false positive results through non-
speciﬁc or off-target effects. Because of the need to avoid this, we have
used drugs within a fairly narrow “therapeutic window”, within
which their speciﬁc effects are clear and signiﬁcant, but frequently
not absolute. It is not unusual, therefore, that many of the positive
controls for the activity of the drugs used in this study show
signiﬁcant but incomplete inhibition, and it would be unwarranted
to infer that there are multiple pathways, on this basis alone. In spite
of the precautions we have taken, the possibility remains that more
precisely targeted approaches may in the future alter some details of
the pathway we present. The ideal approach would be a forward
genetic system that enabled one to manipulate the expression of
macrophage genes in a highly speciﬁc and controlled manner, using
constructs such as the dominant negative Dynamin 2 gene, previously
evaluated in the RAW264.7 cell line (Ghigo et al., 2008). However, the
macrophage is an intrinsically refractory cell type, efﬁciently degrad-
ing exogenous nucleic acids, responding to attempted transfection by
vigorous inﬂammatory reactions and apoptosis, being terminally
differentiated and intrinsically genetically variable. Macrophage-like
cell lines, such as Monomac, U937, THP-1 and HL-60 share some
features with authentic macrophages, but fail to recapitulate key
features of HIV interaction and surface molecule regulation. As a
complement to increasingly sophisticated methods for macrophage
transfection or the development of new and better lines, we have
developed a powerful system for the routine differentiation of
authentic macrophages from human embryonic stem cells (Karlsson
et al., 2008) The macrophages produced by this system have the key
features of primary cells, including susceptibility only to macrophage-
tropic strains of HIV, phagocytosis and the respiratory burst. We
hope to use this system in the future to perform the key genetic
experiments that will enable us to conﬁrm and reﬁne the infection
pathway we describe here.
Taken together, our results indicate that HIV-1 entry into
macrophages requires some of the same key factors implicated in
macropinocytotic entry of other viruses, such as actin remodelling
through Rac, Pak1 and Na+/H+ exchangers. However, it is distinct
from macropinocytosis in requiring dynamin but not requiring PI-3
kinases, vesicle acidiﬁcation and myosin II. This previously uniden-
tiﬁed entry route, which we provisionally term PHEEM, highlights the
endocytic complexities of macrophages, and demonstrates that HIV
has evolved to take advantage of diverse routes of entry into its
alternative cellular hosts. Identiﬁcation of the cellular pathways and
signalling components that mediate productive virus entry into
primary cells is of much importance, and it will increase knowledge
for the design of rational inhibitor molecules that will be capable of
preventing virus entry of HIV-1 into all cell types.
Materials and methods
Cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated using
Ficoll-Paque Plus (GE Healthcare) density gradient centrifugation
from the blood of healthy donors. Monocytes were isolated by CD14
positive selection using anti-CD14 magnetic beads (Miltenyi Biotec)
according to the manufacturer's instructions. Monocytes were seeded
at a density of 1.5×105 cells/cm2 in 6-well plates, 12-well plates, 24-well plates or T25 ﬂasks and differentiated for 7–9 days prior to use.
Unless stated all monocytes were differentiated in RPMI 1640 media
(PAA)with 10% Fetal Calf Serum (FCS; PAA), 2 mM L-glutamine (PAA),
100 U/mL penicillin and 100 μg/mL streptomycin (PAA), supplemen-
ted with 100 ng/mL (approximately 1.7×104 U/mL) recombinant
human M-CSF (R&D Systems), to produce M-CSF macrophages.
Alternatively, monocytes were cultured in RPMI FCS supplemented
with 50 ng/mL (approximately 4.15 U/mL) recombinant human GM-
CSF (R&D systems) or X-Vivo (Lonza) containing 1% autologous serum
(AS). After 7 days of differentiation X-Vivo macrophages were
classically activated by treatmentwith 20 ng/mL IFN-γ (R&D systems)
and 100 ng/mL LPS (Sigma) or alternatively activated with 20 ng/mL
IL-4 (R&D systems) for 18 h. Monocytes were differentiated into DCs
by incubation with RPMI FCS containing 50 ng/mL GM-CSF and 50 ng/
mL IL-4 for 6 days. For a further 2 days, DCs either remained in GM-
CSF/IL-4 media to maintain them as immature DCs or were matured
by the addition of 1 μg/mL LPS. CD4+ T cells were isolated from the
CD14-negative cell population by negative selection with magnetic
beads (CD4+ T cell isolation kit II, Miltenyi Biotec) according to the
manufacturer's protocol. CD4+ T cell were cultured at a density of
1.0×106 cells/mL and activated in RPMI 10% FCS supplemented with
recombinant human IL-2 (70 U/mL) and 1 μg/mL phytohemagglutinin
(PHA; Sigma) for 5 days.
Virus stocks
HIV-1 BaL was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, from S. Gartner
(Gartner et al., 1986) and viral stocks were generated in differenti-
ated, unstimulated PBMCs cultured in X-Vivo with 1% AS. Infected cell
supernatants were harvested 14–21 days after infection and frozen
for use in infectivity assays. Virus stocks with proviral DNA removed
were generated for qPCR experiments by treatment with 100 μg/mL
DNase I (Sigma). To generate single round replication competent
virus, 293T cells were regularly passaged in DMEM (PAA) with 10%
FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL strepto-
mycin. Cells seeded into T75 ﬂasks were transfected with pNL4.3.Luc.
R-E- (2 μg) and pJRFL Env (1.5 μg) using Fugene 6 according to
manufacturer's instructions. The NL4.3 JRFL virus was harvested 48 h
later, passed through a 0.44 μm ﬁlter and frozen.
Pharmacological inhibitors
5-(N,N-Dimethyl)amiloride hydrochloride (DMA), 5-(N-Ethyl-N-
isopropyl)amiloride (EIPA), 5-(N,N-Hexamethylene)amiloride
(HMA), cytochalasin D (cytoD), baﬁlomycin A1 (bafA), dynasore
monohydrate, chlorpromazine (chlor), LY-294,002 hydrochloride,
blebbistatin (bleb) and IPA-3 were all obtained from Sigma.
Latrunculin A (latA), wiskostatin (wisko), Clostridium difﬁcile Toxin
B, rac1 inhibitor NSC23766, wortmannin, ROCK inhibitors Y-27632
and H1152, and Gö 6976 were obtained from Calbiochem. Jasplaki-
nolide (jasp) was obtained from Invitrogen.
Treatment of macrophages with pharmacological inhibitors and cell
viability assays
Macrophages were incubated with varying concentrations of
pharmacological inhibitors for 1 h at 37 °C prior to infection,
immunoﬂuorescence or ﬂow cytometry analysis. Dynasore monohy-
drate and Clostridium difﬁcile Toxin B were incubated with the cells in
serum-free RPMI whereas as all other inhibitors were incubated in
RPMI 10% FCS. Most drugs are dissolved in DMSO so to exclude for any
effects of this solvent the control cells were incubated in the same
dilution of DMSO as used for the drug (never more than 0.2% of
volume). Drugs dissolved in water (Clostridium difﬁcile Toxin B, Rac1
inhibitor NSC23766, clathrin inhibitor chlorpromazine and ROCK
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cells. Following infection, cells were cultured in RPMI FCS M-CSF. To
determine cell viability following treatment with pharmacological
inhibitors for either 1 h or 2.5 h, macrophages were incubated with
CellTiter 96® AQueous One Solution Cell Proliferation Assay reagent
(Promega) diluted 1 in 6 in serum-free RPMI or RPMI FCS for 1 h at
37 °C. The absorbance of the supernatant was then read at 490 nm
using a Molecular Devices E max precision microplate reader and
SoftMax Pro software version 4.0. Background absorbance readings
from reagent and media alone were deducted and the values
expressed as a percentage of untreated cells.
Quantitative PCR
After 1 h treatment with pharmacological inhibitor, macrophages
were infected in 12-well plates with 500 μL of DNase I treated HIV-1
BaL by spinoculation in a sealed plate spinning centrifuge at 2000×g
for 90 min at 37 °C. Where possible, inhibitors were also added to the
virus inoculum during spinoculation, although due to toxicity DMA,
EIPA, cytoD, latA, and jasp were not. The virus inoculumwas removed,
cells were overlaid with RPMI FCS M-CSF and infections were left to
proceed for 28 h. In some experiments, 7.5 μg/mL T-20 fusion
inhibitor (AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH, from Roche)was added following removal of drug
and virus to prevent infection occurring in the absence of drug
treatment. Cells were harvested by scraping and DNA was extracted
using DNeasy Blood and Tissue Kit (Qiagen) according to the
manufacturer's instructions. The qPCR assay was performed either
using a ﬂuorescent probe assay as described previously (Carter et al.,
2009) or using a SYBR® Green protocol with the same primers and
standards. In both cases, the HIV-1 copy number was normalised to
the number of cells using a β actin control kit (Eurogentec). The target
of the HIV-1 primers is the region of the HIV cDNA between the 5′ LTR
sequence and the 5′ end of the gag gene; this sequence is present in
late stage reverse transcripts. SYBR® Green reaction mixtures
contained 2× MESA Green qPCR MasterMix Plus for SYBR® Assay No
ROX (Eurogentec), 100 nM of each primer, and either 2 μL of standard
or 7 μL of sample DNA, in a total reaction volume of 25 μL. A PTC 200
Peltier Thermal Cycler PCR machine (MJ Research) was used with the
following SYBR® Green programme: 95 °C for 10 min, 40 cycles of
95 °C for 30 s, 62 °C for 1 min, 72 °C for 1 min, with a plate read after
each cycle, followed by a ﬁnal 1 min at 95 °C and a melting curve from
55 °C to 95 °C (read every 1 °C). Data were collected and analysed
using OpticonMonitor software, version 2.03.
ELISA for p24 antigen
To measure multiple rounds of HIV infection, drug-treated macro-
phages were infected in 12-well plates with HIV-1 BaL for 2 h at 37 °C.
The inoculumwas removed and replacedwith RPMI FCSM-CSFwithout
drug. Over a 14–16 day period, supernatant samples were taken at
intervals and kept at −80 °C. Samples were diluted in TES (1× Tris
buffered saline [TBS], 1% Empigen [Fluka], 10% FCS, 0.05% Tween 20),
heat inactivated and p24 levels quantiﬁed by p24 ELISA as described
previously (Carter et al., 2009).
Antibody staining, ﬂuorescent probe uptake and ﬂow cytometry
Macrophages were detached on ice with 5 mM EDTA and 12 mM
lidocaine inPBS, andwashedoncewith FACSbuffer (PBS, 0.01%NaN3, 1%
FCS, 10 μg/mL human IgG [Sigma]). 1×105 cells were incubated with
5 μg/mL directly conjugated mouse anti-human antibodies to CD4
(clone 1180), CCR5 (clone 45531) or appropriate isotype control (all
R&D systems). Cellswereﬁxed in 4% formaldehyde. Flowcytometrywas
carried out using a Becton-Dickinson FACSCalibur ﬂow cytometer with10,000 events collected and data were analysed using FlowJo software,
version 7.1.3.
Macrophages treated with inhibitors for 1 h at 37 °C were incubated
with 70 kDa Dextran-Texas Red (Dex-TR; 166 μg/mL, Invitrogen),
150 kDa Dextran-FITC (Dex-FITC; 250 μg/mL, Sigma), or transferrin
Alexa Fluor 488 (20 μg/mL, Invitrogen), in the continued presence of
drug for 30 min at 37 °C. Cells were washed once and lifted as above, and
analysed by ﬂow cytometry as described. Uptake in drug-treated
macrophages was compared to untreated cells, and background binding
levels from cells that remained on ice with the ﬂuorescent marker were
subtracted. To visualise virus and70 kDadextran, NL4.3 JRFL virus capable
of a single roundof infectionwas spinoculated (1 h, 4 °C, 700×g) ontoday
7 macrophage monolayers seeded onto glass coverslips in 24 well plates.
Cells were washed with ice-cold PBS and incubated in RPMI containing
10 μg/mLDex-TR for 40 min at 37 °C. Cellswereﬁxed in4% formaldehyde,
quenched in 80 mMglycine in PBS andpermeabilised in buffer containing
1%FCS, 0.1% saponin and10 μg/mLhuman IgG in PBS. Todetect virus, cells
were stainedwithmouse anti-HIVp17 diluted 1 in 500 (clone 4C9, Centre
for AIDS Reagents, NIBSC) followed by Alexa Fluor 647 conjugated goat
anti-mouse IgG2a antibody diluted 1 in 400 (clone A21131, Invitrogen).
Coverslips were mounted on slides using Mowiol and images collected
using a Zeiss Pascal Microscope.
Western blotting
Macrophages (1×107) were harvested by scraping and lysed for
30 min on ice in lysis buffer consisting of 50 mMTris–HCl, pH 8 (Sigma),
150 mM NaCl (Sigma), 1% (w/v) n-Dodecyl β-D-maltoside (Sigma), 1×
protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail 2
(1 in 100 dilution, Sigma). Lysateswere centrifuged for 10 min at 4 °C to
separate insoluble material and cleared lysate was resuspended in 1×
Laemmli sample buffer under reducing conditions and heated for
10 min at 90 °C. Lysates equivalent to 5×105, 1×106 or 2×106 cells
were run on a 10% SDS-PAGE protein gel with Biorad precision plus
protein standards. Protein was transferred onto 0.2 μm PVDF mem-
branes, andmembranes were incubatedwith primary rabbit polyclonal
anti-caveolin-1 antibody (Abcam ab18199, 1.5 μg/mL), mouse mono-
clonal anti-caveolin-2 (BD Biosciences clone 610684, 1 μg/mL) or
polyclonal anti-human GAPDH antibody (R&D systems, 2275-PC-1, 1
in 5000). To detect primary antibody binding, membranes were
incubated with secondary antibodies (LI-COR Biosciences); either goat
anti-mouse 800 CW (926-32201) or goat anti-rabbit 680 CW (926-
32221) diluted to 66.6 ng/mL.Washedmembranes were scanned using
the quantitative western blotting imaging system Odyssey (LI-COR
Biosciences).
Reverse transcription-PCR
Total RNAwas extracted fromU87.CD4.CCR5 cells andmacrophages
differentiated inM-CSF or GM-CSF using a Qiagen RNeasy kit according
the manufacturer's instructions. Ambion RETROscript kit was used to
produce cDNA (1 μg of RNA per reaction with Oligo-dT primers) and to
performRT-PCR. Positive control primers to ribosomal protein S15 gene
were suppliedwith the kit, and cav-1 primerswere as follows: sense 5′-
AGCATGTCTGGGGGTAAATACG-3′ and antisense 5′-CCTCCATCCCT-
GAAATGTCCT-3′ (Silva et al., 2005). As a control, the same RNA used
to produce the cDNA was also tested in the PCR reaction to check for
genomic DNA contamination.
Statistical analysis
Statistical analyses were performed using two-tailed one sample t-
test of normalised data setswithGraphPadPrismversion 4. The testwas
carried out to determinewhether themeans of our normalised data sets
were signiﬁcantly different from a hypothetical mean value of 1 (100%)
which represents control cells. Stars indicate the p value: *=signiﬁcant
248 G.C. Carter et al. / Virology 409 (2011) 234–250p=0.05–0.01, **=very signiﬁcant p=0.01–0.001, ***=extremely
signiﬁcant pb0.001.
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